Latest news and press releases about Neurogene Inc. (NGNE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Price
| Price | $32.41 |
| Market Cap | $512M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.35 |
| EV / EBITDA | -4.69 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -45.11% |
| Return on Invested Capital | -53.72% |
| Return on Assets | -45.47% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · ALMS · AUTL · BNTC · FULC · LCTX · OCGN
Explore sector: Healthcare · Biotechnology
More sections of NGNE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks